Lornit 500 Tablet contains L-Ornithine L-Aspartate 500 mg, a compound widely used in the management of hepatic encephalopathy and other liver-related disorders. L-Ornithine L-Aspartate acts by facilitating the detoxification of ammonia, a neurotoxic substance that accumulates in patients with liver dysfunction, thereby improving mental status and reducing symptoms associated with hepatic encephalopathy. The active ingredients promote the urea cycle and glutamine synthesis, enhancing ammonia clearance from the bloodstream. Lornit 500 is indicated as an adjunct therapy in chronic liver diseases, including cirrhosis and acute liver failure, where elevated blood ammonia levels contribute to neurological impairment. The tablet is typically administered orally, with dosage tailored according to the severity of the condition and patient response. It is generally well-tolerated, with minimal adverse effects; however, patients should be monitored for any hypersensitivity reactions or gastrointestinal disturbances. Lornit 500 should be used under medical supervision, especially in patients with renal impairment or concurrent medication use. This formulation provides an effective approach to managing hyperammonemia, improving patient outcomes by reducing the risk of hepatic encephalopathy progression and enhancing quality of life in liver disease patients.